Drugs in Dev. Infections and Infectious Diseases
Phase II/ Phase III
India 
Lead Product(s) : Gam-COVID-Vac
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Russian Direct Investment Fund
Deal Size : Inapplicable
Deal Type : Inapplicable
Dr. Reddy's and RDIF Commence Clinical Trials for Sputnik V Vaccine in India
Details : After obtaining the requisite clearance from the Central Drugs Laboratory, Dr. Reddy's Laboratories and RDIF have begun adaptive phase 2/3 clinical trials for the Sputnik V vaccine in India. The trial is a multicenter and randomised controlled safety and...
Product Name : Sputnik V
Product Type : Vaccine
Upfront Cash : Inapplicable
January 12, 2020
Lead Product(s) : Gam-COVID-Vac
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Russian Direct Investment Fund
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Drug Panel May Review Gennova's mrna Omicron Booster Vaccine
Details : Gemcovac-19 is the first approved mRNA based Covid-19 vaccine developed with the use of genetically engineered mRNA which instructs the cells to make the S-protein found on the surface of the Covid-19 virus, causing the body to create antibodies.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
April 18, 2023
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HGCO19
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Gennova Biopharma Submits Final Vaccine Trial Data to Regulator
Details : Company has conducted phase-2/3 trials of vaccine candidates to evaluate its safety, immunogenicity and tolerability on 4,000 participants, for first indigenously developed HGCO19, mRNA vaccine for Covid-19.
Product Name : HGCO19
Product Type : Vaccine
Upfront Cash : Inapplicable
December 03, 2022
Lead Product(s) : HGCO19
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HGCO19
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
India's First Homegrown mRNA COVID-19 Vaccine Currently Under Final Clinical Trial Stages: Govt
Details : Gennova's synthetic, self-replicating India's first homegrown mRNA vaccine is in Phase III Clinical Trials for the treatment of COVID-19 is currently under final clinical trial stages. .
Product Name : HGCO19
Product Type : Vaccine
Upfront Cash : Inapplicable
November 02, 2022
Lead Product(s) : HGCO19
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BECOV2D
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Corbevax is an RBD protein based sub-unit vaccine against the coronavirus infections. Corbevax is based on a protein antigen technology that binds to the Angiotensin Converting Enzyme-2 (ACE2) receptor on the host cell membrane.
Product Name : Corbevax
Product Type : Vaccine
Upfront Cash : Inapplicable
October 19, 2021
Lead Product(s) : BECOV2D
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BECOV2D
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Currently, phase 2/3 clinical trials of the second indigenously developed Corbevax, an RBD protein sub-unit vaccine to be administered in adults aged 18 years to 80 years, is underway and the results are likely to be declared this month.
Product Name : Corbevax
Product Type : Vaccine
Upfront Cash : Inapplicable
October 13, 2021
Lead Product(s) : BECOV2D
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BECOV2D
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
New Covid vaccine: Bio E May submit Corbevax Trial Data This Month
Details : Corbevax is in phase-3 trials and likely to complete all the studies by end of November which is when company is expecting licence. The licence for children should follow one month later.
Product Name : Corbevax
Product Type : Vaccine
Upfront Cash : Inapplicable
September 11, 2021
Lead Product(s) : BECOV2D
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BBV87,Aluminium Hydroxide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : The International Vaccine Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
IVI and BBIL Launch Global Chikungunya Vaccine Phase II/III trial in Costa Rica
Details : BBIL’s BBV87 vaccine is an inactivated whole virion vaccine based on strain derived from an East, Central, South African (ECSA) genotype. IVI is advancing clinical development of BBV87 to evaluate safety and immunogenicity of 2-dose regimen of BBV87 Ch...
Product Name : BBV87
Product Type : Vaccine
Upfront Cash : Inapplicable
August 24, 2021
Lead Product(s) : BBV87,Aluminium Hydroxide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : The International Vaccine Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BBV154,BBV152
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bharat Biotech Gets Nod for Phase 2/3 Trials of Intranasal Covid Vaccine
Details : Phase 1 trial of the adenoviral intranasal vaccine, BBV154 in healthy volunteers of age groups ranging from 18 to 60 years was well tolerated, the science and technology ministry said in a release on Friday.
Product Name : BBV154
Product Type : Vaccine
Upfront Cash : Inapplicable
August 14, 2021
Lead Product(s) : BBV154,BBV152
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Inactivated Salk Polio Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
SII Gets CDSCO Committee Nod to Conduct Clinical Trial of Reduced Inactivated Salk Polio Vaccine
Details : Poliomyelitis vaccine (Inactivated) is indicated for active immunization of infants, children and adults for the prevention of poliomyelitis caused by poliovirus type 1, 2 and 3.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
July 14, 2021
Lead Product(s) : Inactivated Salk Polio Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
